Lake Street Maintains Buy on Cellebrite DI, Lowers Price Target to $15
Lake Street analyst Eric Martinuzzi maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $21 to $15.
Stocks · News reference
Cellebrite Shares Plunge Thursday: What's Driving the Move?
Shares of Cellebrite are trading sharply lower on Thursday following the release of second-quarter financial results that missed top-line expectations alongside downgraded revenue guidance for the third quarter and full year 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
JP Morgan Maintains Overweight on Cellebrite DI, Lowers Price Target to $16
JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:CLBT) with a Overweight and lowers the price target from $20 to $16.
DA Davidson Maintains Buy on Cellebrite DI, Lowers Price Target to $15
DA Davidson analyst Rudy Kessinger maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $22 to $15.
Needham Maintains Buy on Cellebrite DI, Lowers Price Target to $12.5
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $15 to $12.5.